cisplatin + gefitinib + vinorelbine

This is a combination regimen consisting of three distinct anti-cancer drugs—cisplatin, gefitinib, and vinorelbine—used primarily in the treatment of non-small cell lung cancer (NSCLC) and potentially other solid tumors. Each component has a different mechanism of action: - Cisplatin is a platinum-based chemotherapy that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling pathways involved in tumor cell proliferation and survival. - Vinorelbine is a vinca alkaloid chemotherapy agent that inhibits microtubule assembly, thereby preventing mitosis and inducing cell death[1][2][3][5][6]. The combination aims to target cancer cells through multiple mechanisms for improved efficacy.